Policy Brief: CSAM-SMCA in Support of the Decriminalization of Drug Use and Possession for Personal Use

https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE  Parliamentary submission
DATE  2020-08-13
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Authorizing Cannabis for Medical Purposes

Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Populated health, health equity, public health

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2010-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

Cannabis for medical purposes is a complex issue. The Canadian Medical Association (CMA) recognizes the unique requirements of these individuals suffering from a terminal illness or chronic disease for which conventional treatments have not been effective and for whom cannabis (marijuana) offers a palliative role.

However, there is a need for more scientific evidence to support the use of cannabis for medical purposes. This evidence is important for patients and their caregivers, as well as for health care professionals.

The CMA supports the following recommendations:

1. Increased support for the advancement of scientific knowledge about the medical use of cannabis, such as through the development of research grant opportunities.
2. Increased support for the development of pharmaceutical preparations for cannabis.
3. Increased support for research into the best practices for the medical use of cannabis.
4. Increased support for the development of a comprehensive national strategy for the medical use of cannabis.

The CMA encourages all levels of government to support the development of a comprehensive national strategy for the medical use of cannabis, which includes increased support for research, development of pharmaceutical preparations, and best practices for the medical use of cannabis.
MEDICATION USE AND SENIORS

(UPDATE 2017)

CMA POLICY

Medication use and seniors (Update 2017)

https://policybase.cma.ca/link/policy10151

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2011-05-28

REPLACES
Medication use and seniors

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE: Response to consultation
DATE: 2019-02-20
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs, Population health, health equity, public health

Documents

CMA response:
HEALTH CANADA CONSULTATION ON EDIBLE CANNABIS, EXTRACTS & TOPICALS
February 20, 2019

CMA Policybase - Canadian Medical Association
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
        Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE: Response to consultation
DATE: 2018-10-02
TOPICS:
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA submission:
IMPLEMENTATION OF NATIONAL PHARMACARE

Submission to the Advisory Council
November 2018
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE: Response to consultation
DATE: 2018-09-06
TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

https://policybase.cma.ca/link/policy13931

POLICY TYPE Policy endorsement

DATE 2018-08-30

TOPICS Pharmaceuticals, prescribing, cannabis, drugs
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE  Response to consultation
DATE  2018-08-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

**POLICY TYPE**
Response to consultation

**DATE**
2018-07-18

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

The Canadian Medical Association welcomes the opportunity to participate in the development of front-of-package labelling on nutrition and health claims to help families make informed choices about unhealthy food and ingredient claims.

The CMA recommends that the front-of-package labelling system should be comprehensive, clear and consistent across the country.

The CMA recommends that the front-of-package labelling system should be comprehensive, clear and consistent across the country.

The CMA recommends that the front-of-package labelling system should be comprehensive, clear and consistent across the country.
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE  Parliamentary submission
DATE  2018-04-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

POLICY TYPE  Parliamentary submission
DATE  2018-02-15
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE  2018-01-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA submission:
PROPOSED APPROACH TO THE REGULATION OF CANNABIS
Submission to Health Canada
January 23, 2018
Excise duty framework for cannabis products

https://policybase.cma.ca/link/policy13799

POLICY TYPE  Response to consultation
DATE  2017-12-07
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE          Response to consultation
DATE                 2017-11-7
TOPICS               Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescription only.

November 7, 2017